- Home
- NLSP vs GNPX Comparison
NLSP vs GNPX Comparison
Compare NLSP & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- GNPX
- Stock Information
- Founded
- NLSP 2015
- GNPX 2009
- Country
- NLSP Switzerland
- GNPX United States
- Employees
- NLSP N/A
- GNPX N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- GNPX Health Care
- Exchange
- NLSP Nasdaq
- GNPX Nasdaq
- Market Cap
- NLSP 6.9M
- GNPX 6.1M
- IPO Year
- NLSP 2021
- GNPX 2018
- Fundamental
- Price
- NLSP $1.49
- GNPX $0.30
- Analyst Decision
- NLSP
- GNPX Strong Buy
- Analyst Count
- NLSP 0
- GNPX 1
- Target Price
- NLSP N/A
- GNPX $10.00
- AVG Volume (30 Days)
- NLSP 31.2K
- GNPX 6.0M
- Earning Date
- NLSP 05-14-2025
- GNPX 05-13-2025
- Dividend Yield
- NLSP N/A
- GNPX N/A
- EPS Growth
- NLSP N/A
- GNPX N/A
- EPS
- NLSP N/A
- GNPX N/A
- Revenue
- NLSP N/A
- GNPX N/A
- Revenue This Year
- NLSP N/A
- GNPX N/A
- Revenue Next Year
- NLSP N/A
- GNPX N/A
- P/E Ratio
- NLSP N/A
- GNPX N/A
- Revenue Growth
- NLSP N/A
- GNPX N/A
- 52 Week Low
- NLSP $1.30
- GNPX $0.22
- 52 Week High
- NLSP $18.40
- GNPX $4.09
- Technical
- Relative Strength Index (RSI)
- NLSP 42.38
- GNPX 39.82
- Support Level
- NLSP $1.30
- GNPX $0.22
- Resistance Level
- NLSP $1.60
- GNPX $0.41
- Average True Range (ATR)
- NLSP 0.10
- GNPX 0.06
- MACD
- NLSP 0.02
- GNPX -0.00
- Stochastic Oscillator
- NLSP 54.29
- GNPX 25.00
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.